ES2513394T3 - Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un antiepiléptico - Google Patents

Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un antiepiléptico Download PDF

Info

Publication number
ES2513394T3
ES2513394T3 ES09778335.1T ES09778335T ES2513394T3 ES 2513394 T3 ES2513394 T3 ES 2513394T3 ES 09778335 T ES09778335 T ES 09778335T ES 2513394 T3 ES2513394 T3 ES 2513394T3
Authority
ES
Spain
Prior art keywords
methylpropyl
dimethylamino
phenol
ethyl
antiepileptic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09778335.1T
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2513394(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2513394T3 publication Critical patent/ES2513394T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinación que comprende como componente(s): (a) al menos un 3-(3-dimetilamino-1-etil-2-metilpropil)fenol de fórmula (I),**Fórmula** opcionalmente en forma de uno de sus estereoisómeros puros, en particular de un enantiómero o un diastereoisómero, en forma de racemato o en forma de mezcla de sus estereoisómeros, en particular de enantiómeros y/o diastereoisómeros, en cualquier proporción de mezcla, o cualquier sal de adición de ácido correspondiente del mismo, y (b) al menos un antiepiléptico seleccionado de entre el grupo consistente en topiramato, lamotrigina, carbamazepina, lacosamida, levitiracetam y retigabina.
ES09778335.1T 2008-09-05 2009-09-04 Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un antiepiléptico Active ES2513394T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
EP08015625 2008-09-05
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
ES2513394T3 true ES2513394T3 (es) 2014-10-27

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14000597T Active ES2719900T3 (es) 2008-09-05 2009-09-04 Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y pregabalina o gabapentina
ES09778335.1T Active ES2513394T3 (es) 2008-09-05 2009-09-04 Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un antiepiléptico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14000597T Active ES2719900T3 (es) 2008-09-05 2009-09-04 Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y pregabalina o gabapentina

Country Status (28)

Country Link
US (1) US20100063148A1 (es)
EP (2) EP2735338B1 (es)
JP (4) JP5731387B2 (es)
KR (3) KR101730924B1 (es)
CN (2) CN102159284B (es)
AR (2) AR073361A1 (es)
AU (3) AU2009289776A1 (es)
BR (1) BRPI0920521A2 (es)
CA (1) CA2735857C (es)
CL (1) CL2011000317A1 (es)
CO (1) CO6382142A2 (es)
CY (2) CY1115751T1 (es)
DK (2) DK2331210T3 (es)
EC (1) ECSP11010869A (es)
ES (2) ES2719900T3 (es)
HR (2) HRP20140663T1 (es)
HU (1) HUE043278T2 (es)
IL (3) IL211135A (es)
LT (1) LT2735338T (es)
MX (1) MX2011002339A (es)
PE (5) PE20142371A1 (es)
PL (2) PL2331210T3 (es)
PT (2) PT2331210E (es)
RU (2) RU2571501C2 (es)
SI (2) SI2735338T1 (es)
TR (1) TR201904388T4 (es)
WO (1) WO2010025931A2 (es)
ZA (1) ZA201101449B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
RU2589692C2 (ru) * 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
MX2013000946A (es) 2010-07-30 2013-02-27 Toray Industries Agente terapeutico o agente profilactico para el dolor neuropatico.
MX348831B (es) * 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
JP6038138B2 (ja) * 2011-07-29 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−［（１ｓ，２ｓ）−３−（ジメチルアミノ）−１−エチル−２−メチルプロピル］フェノールのくも膜下投与または硬膜外投与
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
JP6360488B2 (ja) * 2012-11-01 2018-07-18 トレント・ファーマシューティカルズ・リミテッドＴｏｒｒｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 非経口投与のためのタペンタドールの薬学的組成物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
EP3800177B1 (en) 2015-12-22 2025-01-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
IL148019A0 (en) * 1999-08-20 2002-09-12 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and an anticonvulsant drug
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
PL372210A1 (en) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
HRP20110271T1 (hr) * 2006-04-28 2011-05-31 Grnenthal Gmbh Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
EP2250143B1 (en) * 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물

Also Published As

Publication number Publication date
JP5731387B2 (ja) 2015-06-10
DK2735338T3 (en) 2019-04-23
HRP20190500T1 (hr) 2019-08-09
KR101641519B1 (ko) 2016-07-21
CY1121492T1 (el) 2020-05-29
JP2017071636A (ja) 2017-04-13
IL237392A0 (en) 2015-04-30
MX2011002339A (es) 2011-04-04
HK1198145A1 (en) 2015-03-13
WO2010025931A2 (en) 2010-03-11
KR101730924B1 (ko) 2017-04-27
WO2010025931A3 (en) 2010-06-17
SI2331210T1 (sl) 2014-10-30
PE20142357A1 (es) 2015-02-04
PT2331210E (pt) 2014-08-25
CA2735857A1 (en) 2010-03-11
ES2719900T3 (es) 2019-07-16
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
KR20160086981A (ko) 2016-07-20
CN105520924A (zh) 2016-04-27
AU2009289776A1 (en) 2010-03-11
IL237391A (en) 2017-12-31
AU2016203053B2 (en) 2018-01-25
JP2012501986A (ja) 2012-01-26
KR20170048602A (ko) 2017-05-08
IL211135A (en) 2017-09-28
CN105520924B (zh) 2019-04-09
PE20142372A1 (es) 2015-02-04
HUE043278T2 (hu) 2019-08-28
PL2331210T3 (pl) 2014-12-31
CN102159284A (zh) 2011-08-17
IL211135A0 (en) 2011-04-28
IL237392B (en) 2019-08-29
TR201904388T4 (tr) 2019-05-21
AR117613A2 (es) 2021-08-18
KR20110057144A (ko) 2011-05-31
ZA201101449B (en) 2011-10-26
PT2735338T (pt) 2019-05-24
JP2015096530A (ja) 2015-05-21
PE20110291A1 (es) 2011-06-04
EP2331210A2 (en) 2011-06-15
AU2018202879A1 (en) 2018-05-17
CL2011000317A1 (es) 2011-06-17
EP2735338A1 (en) 2014-05-28
AU2016203053A1 (en) 2016-06-02
AR073361A1 (es) 2010-11-03
CA2735857C (en) 2019-05-28
US20100063148A1 (en) 2010-03-11
CN102159284B (zh) 2015-12-09
PE20190914A1 (es) 2019-06-26
SI2735338T1 (sl) 2019-04-30
EP2331210B1 (en) 2014-07-09
HK1159011A1 (en) 2012-07-27
BRPI0920521A2 (pt) 2018-01-16
EP2735338B1 (en) 2019-02-06
PE20142371A1 (es) 2015-02-04
ECSP11010869A (es) 2011-04-29
PL2735338T3 (pl) 2019-07-31
IL237391A0 (en) 2015-04-30
DK2331210T3 (da) 2014-08-11
JP2019131578A (ja) 2019-08-08
RU2674150C1 (ru) 2018-12-05
HRP20140663T1 (hr) 2014-10-10
AU2018202879B2 (en) 2020-03-12
CY1115751T1 (el) 2017-01-25
CO6382142A2 (es) 2012-02-15
RU2011112444A (ru) 2012-10-10
RU2571501C2 (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
EA201300756A1 (ru) Композиции для осветления цвета кожи
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
AR073361A1 (es) Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso
CL2012000537A1 (es) Mezcla fungicida sinergica que comprende un compuesto derivado de 5-fluoro-2-{(4-metilbenzil)oxi}pirimidina-4-amino y otro fungicida; y composicion fungicida que la comprende.
CR11420A (es) Moduladores de gpr40 bifenilo sustituidos
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ATE515491T1 (de) Herstellung von 3-ä(1r,2r)-3-(dimethylamino)- 1ethyl-2-methylpropylüphenol
CR20120213A (es) Métodos para el tratamiento del cáncer usando antagonistas de notch
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CO6390029A2 (es) Polimorfos de (s)-3-amino-metil-7-(hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
UY31015A1 (es) Mezclas pesticidas que comprenden compuestos de cianosulfoximina
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
ZA201006087B (en) Kit, composition, product or medicament for treating cognitive impairment
EP2274011A4 (en) ANTIBODY-TIED SYNTHETIC VESICLE WITH ACTIVE MOLECULES
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
DK2478054T3 (da) Polyamidsammensætning, som indeholder polyamid 4,10
BRPI0916561A2 (pt) composição amaciante líquida, método de estabilização de uma composição condicionadora de tecidos líquida.
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
CR20110660A (es) Mezclas fungicidas
BR112012014621A2 (pt) processo para a preparação de compostos de quelato